Pharmaceutical Commerce - February 2023 Issue (PDF)

The industry veteran will lead the company’s next phase of growth, focusing on faster treatment initiation through integrated digital platforms and optimized fulfillment strategies.

Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.

Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework.

Engaging the full workforce—from HR to R&D—can elevate launch outcomes, build trust, and create long-term brand ambassadors.